Aug 10 (Reuters) - Gemini Therapeutics Inc :
* GEMINI THERAPEUTICS AND DISC MEDICINE ANNOUNCE MERGER AGREEMENT
* GEMINI THERAPEUTICS INC - COMBINED COMPANY IS EXPECTED TO HAVE APPROXIMATELY $175 MILLION OF CASH OR CASH EQUIVALENTS AT CLOSE
* GEMINI THERAPEUTICS INC - UPON SHAREHOLDER APPROVAL, COMBINED COMPANY IS EXPECTED TO OPERATE UNDER NAME DISC MEDICINE, INC.
* GEMINI THERAPEUTICS INC - PRE-MERGER GEMINI SHAREHOLDERS ARE EXPECTED TO OWN APPROXIMATELY 28% OF COMBINED COMPANY
* GEMINI THERAPEUTICS INC - UPON SHAREHOLDER APPROVAL, COMBINED COMPANY IS EXPECTED TO TRADE ON NASDAQ GLOBAL MARKET UNDER TICKER SYMBOL IRON
* GEMINI THERAPEUTICS INC - PRE-MERGER DISC SHAREHOLDERS ARE EXPECTED TO OWN APPROXIMATELY 72% OF COMBINED COMPANY
* GEMINI THERAPEUTICS - TRANSACTION WILL FUND MULTIPLE CLINICAL STUDIES, INCLUDING CLINICAL TRIALS OF BITOPERTIN FOR ERYTHROPOIETIC PORPHYRIAS
* GEMINI THERAPEUTICS - IN SUPPORT OF MERGER, DISC SECURED COMMITMENTS FROM SYNDICATE OF HEALTHCARE INVESTORS LED BY ACCESS BIOTECHNOLOGY
* GEMINI THERAPEUTICS - TRANSACTION WILL FUND MULTIPLE CLINICAL STUDIES, INCLUDING CLINICAL TRIAL OF DISC-0974 FOR ANEMIA OF MYELOFIBROSIS
* GEMINI THERAPEUTICS - TRANSACTION WILL FUND MULTIPLE CLINICAL STUDIES, INCLUDING CLINICAL TRIAL OF DISC-0974 FOR ANEMIA OF CHRONIC KIDNEY DISEASE
* GEMINI THERAPEUTICS - MERGER AGREEMENT PROVIDES BOARD OF COMBINED CO WILL BE COMPOSED OF 9 MEMBERS, INCLUDING 8 DISC BOARD MEMBERS & 1 FROM GEMINI
* GEMINI THERAPEUTICS - AFTER MERGER, COMBINED CO WILL BE LED BY JOHN QUISEL, CURRENT CEO, PRESIDENT OF DISC MEDICINE, OTHER MEMBERS OF DISC MANAGEMENT
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.